169 related articles for article (PubMed ID: 35228506)
1. Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants.
Parums DV
Med Sci Monit; 2022 Mar; 28():e936523. PubMed ID: 35228506
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.
Madhi SA; Moodley D; Hanley S; Archary M; Hoosain Z; Lalloo U; Louw C; Fairlie L; Fouche LF; Masilela MSL; Singh N; Grobbelaar C; Ahmed K; Benadé G; Bhikha S; Bhorat AE; Bhorat Q; Joseph N; Dheda K; Esmail A; Foulkes S; Goga A; Oommen Jose A; Kruger G; Kalonji DJ; Lalloo N; Lombaard JJ; Lombard Koen A; Kany Luabeya A; Mngqibisa R; Petrick FG; Pitsi A; Tameris M; Thombrayil A; Vollgraaff PL; Cloney-Clark S; Zhu M; Bennett C; Albert G; Faust E; Plested JS; Fries L; Robertson A; Neal S; Cho I; Glenn GM; Shinde V;
Lancet HIV; 2022 May; 9(5):e309-e322. PubMed ID: 35489376
[TBL] [Abstract][Full Text] [Related]
3. Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine.
Underwood E; Dunkle LM; Madhi SA; Gay CL; Heath PT; Kotloff KL; Smith K; Chau G; Galbiati S; McGarry A; Woo W; Cho I; Alves K; Áñez G; Bennett C; Shinde V; Fries L; Mallory RM; Glenn GM; Toback S
Expert Rev Vaccines; 2023; 22(1):501-517. PubMed ID: 37246757
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
Tian JH; Patel N; Haupt R; Zhou H; Weston S; Hammond H; Logue J; Portnoff AD; Norton J; Guebre-Xabier M; Zhou B; Jacobson K; Maciejewski S; Khatoon R; Wisniewska M; Moffitt W; Kluepfel-Stahl S; Ekechukwu B; Papin J; Boddapati S; Jason Wong C; Piedra PA; Frieman MB; Massare MJ; Fries L; Bengtsson KL; Stertman L; Ellingsworth L; Glenn G; Smith G
Nat Commun; 2021 Jan; 12(1):372. PubMed ID: 33446655
[TBL] [Abstract][Full Text] [Related]
5. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses.
Wilkinson B; Patel KS; Smith K; Walker R; Wang C; Greene AM; Smith G; Smith ER; Gurwith M; Chen RT;
Vaccine; 2023 Oct; 41(45):6762-6773. PubMed ID: 37739888
[TBL] [Abstract][Full Text] [Related]
6. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
Formica N; Mallory R; Albert G; Robinson M; Plested JS; Cho I; Robertson A; Dubovsky F; Glenn GM;
PLoS Med; 2021 Oct; 18(10):e1003769. PubMed ID: 34597298
[TBL] [Abstract][Full Text] [Related]
7. Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials.
Smith K; Hegazy K; Cai MR; McKnight I; Rousculp MD; Alves K
Vaccine; 2023 Jun; 41(26):3930-3936. PubMed ID: 37211453
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Dunkle LM; Kotloff KL; Gay CL; Áñez G; Adelglass JM; Barrat Hernández AQ; Harper WL; Duncanson DM; McArthur MA; Florescu DF; McClelland RS; Garcia-Fragoso V; Riesenberg RA; Musante DB; Fried DL; Safirstein BE; McKenzie M; Jeanfreau RJ; Kingsley JK; Henderson JA; Lane DC; Ruíz-Palacios GM; Corey L; Neuzil KM; Coombs RW; Greninger AL; Hutter J; Ake JA; Smith K; Woo W; Cho I; Glenn GM; Dubovsky F;
N Engl J Med; 2022 Feb; 386(6):531-543. PubMed ID: 34910859
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Alves K; Plested JS; Galbiati S; Chau G; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Smith K; Marcheschi A; Pfeiffer S; McFall H; Smith G; Glenn GM; Dubovsky F; Mallory RM;
Vaccine; 2023 Jun; 41(29):4280-4286. PubMed ID: 37271706
[TBL] [Abstract][Full Text] [Related]
10. Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years - United States, July 2022.
Twentyman E; Wallace M; Roper LE; Anderson TC; Rubis AB; Fleming-Dutra KE; Hall E; Hsu J; Rosenblum HG; Godfrey M; Archer WR; Moulia DL; Daniel L; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE
MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(31):988-992. PubMed ID: 35925807
[TBL] [Abstract][Full Text] [Related]
11. Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19.
Mateo-Urdiales A; Sacco C; Petrone D; Bella A; Riccardo F; Del Manso M; Bressi M; Siddu A; Brusaferro S; Palamara AT; Rezza G; Pezzotti P; Fabiani M;
JAMA Netw Open; 2023 Oct; 6(10):e2336854. PubMed ID: 37792377
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
Heath PT; Galiza EP; Baxter DN; Boffito M; Browne D; Burns F; Chadwick DR; Clark R; Cosgrove C; Galloway J; Goodman AL; Heer A; Higham A; Iyengar S; Jamal A; Jeanes C; Kalra PA; Kyriakidou C; McAuley DF; Meyrick A; Minassian AM; Minton J; Moore P; Munsoor I; Nicholls H; Osanlou O; Packham J; Pretswell CH; San Francisco Ramos A; Saralaya D; Sheridan RP; Smith R; Soiza RL; Swift PA; Thomson EC; Turner J; Viljoen ME; Albert G; Cho I; Dubovsky F; Glenn G; Rivers J; Robertson A; Smith K; Toback S;
N Engl J Med; 2021 Sep; 385(13):1172-1183. PubMed ID: 34192426
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
Masuda T; Murakami K; Sugiura K; Sakui S; Schuring RP; Mori M
Vaccine; 2022 May; 40(24):3380-3388. PubMed ID: 35501178
[TBL] [Abstract][Full Text] [Related]
14. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge.
Guebre-Xabier M; Patel N; Tian JH; Zhou B; Maciejewski S; Lam K; Portnoff AD; Massare MJ; Frieman MB; Piedra PA; Ellingsworth L; Glenn G; Smith G
Vaccine; 2020 Nov; 38(50):7892-7896. PubMed ID: 33139139
[TBL] [Abstract][Full Text] [Related]
15. NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses.
Rydyznski Moderbacher C; Kim C; Mateus J; Plested J; Zhu M; Cloney-Clark S; Weiskopf D; Sette A; Fries L; Glenn G; Crotty S
J Clin Invest; 2022 Oct; 132(19):. PubMed ID: 35943810
[TBL] [Abstract][Full Text] [Related]
16. BNT162b2 mRNA COVID-19 Vaccine: First Approval.
Lamb YN
Drugs; 2021 Mar; 81(4):495-501. PubMed ID: 33683637
[TBL] [Abstract][Full Text] [Related]
17. NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.
Marchese AM; Zhou X; Kinol J; Underwood E; Woo W; McGarry A; Beyhaghi H; Áñez G; Toback S; Dunkle LM
Vaccine; 2023 May; 41(22):3461-3466. PubMed ID: 37127523
[TBL] [Abstract][Full Text] [Related]
18. Protein vaccine NVX-CoV2373 elicits functional T cell immunity.
Zhou P
J Clin Invest; 2022 Oct; 132(19):. PubMed ID: 36189797
[TBL] [Abstract][Full Text] [Related]
19. Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
Fix J; Christopher Mast T; Smith K; Baker N
Vaccine; 2024 Apr; 42(9):2161-2165. PubMed ID: 38494410
[TBL] [Abstract][Full Text] [Related]
20. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages.
Bhiman JN; Richardson SI; Lambson BE; Kgagudi P; Mzindle N; Kaldine H; Crowther C; Gray G; Bekker LG; ; Shinde V; Bennett C; Glenn GM; Madhi SA; Moore PL
Sci Rep; 2023 Jan; 13(1):1222. PubMed ID: 36681693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
